hyperphosphataemia in chronic kidney disease
Endocrinology · 2006–2019
10decisions
6medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sevelamer carbonate Management of hyperphosphataemia in patients with chronic kidney disease that require dialysis. | Mar 2019 | Recommended | no section in document |
| sevelamer Hyperphosphataemia in patients undergoing dialysis for chronic kidney disease (adults aged 18 years and over with stage 4 and 5 CKD). | Nov 2017 | Recommended with restriction | none received |
| sucroferric oxyhydroxide Treatment of hyperphosphataemia in patients undergoing dialysis for chronic kidney disease. | Jul 2015 | Noted | no section in document |
| sucroferric oxyhydroxide Treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis. | Nov 2014 | Recommended with restriction | input received |
| lanthanum carbonate hydrate Management of hyperphosphataemia in patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where serum… | Nov 2008 | Recommended | no section in document |
| sevelamer hydrochloride Treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products. | Jul 2007 | Recommended with restriction | no section in document |
| lanthanum carbonate Treatment of hyperphosphataemia in adult patients with chronic renal failure on dialysis whose serum calcium levels are at least 2.60 mmol/L. | Mar 2007 | Not recommended | no section in document |
| sevelamer hydrochloride treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products | Mar 2006 | Recommended | no section in document |
| sevelamer hydrochloride Treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products. | Mar 2006 | Recommended | no section in document |
| sevelamer hydrochloride treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where:… | Nov 2006 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.